REPORT ID 3364

United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Report 2017

Publish Date
13-Dec-17
Pages
98
Format
Electronic (PDF)

In this report, the United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Attention Deficit Hyperactivity Disorder (ADHD) Drugs in these regions, from 2012 to 2022 (forecast).

United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs market competition by top manufacturers/players, with Attention Deficit Hyperactivity Disorder (ADHD) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Eli Lilly
    Perdue Pharma
    Johnson & Johnson
    Janssen Pharmaceuticals, Inc.
    Shire
    Glaxosmith Kline
    Novartis
    Celltech Group

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Stimulants
    Non-Stimulants
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Pediatric
    Adolescent
    Adults

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Report 2017
1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Overview
    1.1 Product Overview and Scope of Attention Deficit Hyperactivity Disorder (ADHD) Drugs
    1.2 Classification of Attention Deficit Hyperactivity Disorder (ADHD) Drugs by Product Category
        1.2.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Stimulants
        1.2.4 Non-Stimulants
    1.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Application/End Users
        1.3.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Pediatric
        1.3.3 Adolescent
        1.3.4 Adults
    1.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Region
        1.4.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Attention Deficit Hyperactivity Disorder (ADHD) Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Attention Deficit Hyperactivity Disorder (ADHD) Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Attention Deficit Hyperactivity Disorder (ADHD) Drugs Status and Prospect (2012-2022)
        1.4.5 New England Attention Deficit Hyperactivity Disorder (ADHD) Drugs Status and Prospect (2012-2022)
        1.4.6 The South Attention Deficit Hyperactivity Disorder (ADHD) Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Attention Deficit Hyperactivity Disorder (ADHD) Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Attention Deficit Hyperactivity Disorder (ADHD) Drugs (2012-2022)
        1.5.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue and Growth Rate (2012-2022)

2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Competition by Players/Suppliers
    2.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Competitive Situation and Trends
        2.4.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Concentration Rate
        2.4.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Attention Deficit Hyperactivity Disorder (ADHD) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Price by Region (2012-2017)

4 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Price by Type (2012-2017)
    4.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Type (2012-2017)

5 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Players/Suppliers Profiles and Sales Data
    6.1 Eli Lilly
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Perdue Pharma
        6.2.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Johnson & Johnson
        6.3.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Janssen Pharmaceuticals, Inc.
        6.4.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Shire
        6.5.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Shire Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Glaxosmith Kline
        6.6.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Novartis
        6.7.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Celltech Group
        6.8.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview

7 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Manufacturing Cost Analysis
    7.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Attention Deficit Hyperactivity Disorder (ADHD) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Attention Deficit Hyperactivity Disorder (ADHD) Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer